Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data

Project: Research project

Project Details

Description

Dr. Seema Khan and Dr. Susan Clare will collaborate with Envisagenics on Aims 2 and 3 of this grant proposal to further develop and validate SpliceIO, a software platform for neoantigen discovery using RNA-seq data. This will be achieved through a large-scale neoantigen validation using mass spectrometry and proof of concept studies in mammary organoids from BRCA1/2 carrier patients at risk of developing breast and/or ovarian cancer.
StatusActive
Effective start/end date7/1/226/30/24

Funding

  • Envisagenics, Inc. (1R44CA265446-01-NU Amendment 1 // 5R44CA265446-02)
  • National Cancer Institute (1R44CA265446-01-NU Amendment 1 // 5R44CA265446-02)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.